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Insertion of additional octarepeats into the prion protein gene
has been genetically linked to familial Creutzfeldt Jakob disease and
hence to de novo generation of infectious prions. The pivotal event
during prion formation is the conversion of the normal prion pro-
tein (PrPC) into the pathogenic conformer PrPSc, which subse-
quently induces further conversion in an autocatalytic manner.
Apparently, an expanded octarepeat domain directs folding of PrP
toward the PrPSc conformation and initiates a self-replicating con-
version process. Here, based on three main observations, we have
provided a model on how altered molecular interactions between
wild-type and mutant PrP set the stage for familial Creutzfeldt
Jakobdiseasewith octarepeat insertions. First, we showed thatwild-
typeoctarepeat domains interact in a copper-dependent and revers-
ible manner, a “copper switch.” This interaction becomes irrevers-
ible upon domain expansion, possibly reflecting a loss of function.
Second, expanded octarepeat domains of increasing length gradu-
ally form homogenous globular multimers of 11–21 nm in the
absence of copper ions when expressed as soluble glutathione
S-transferase fusion proteins. Third, octarepeat domain expansion
causes a gain of function with at least 10 repeats selectively binding
PrPSc in a denaturant-resistant complex in the absence of copper
ions. Thus, the combination of both a loss and gain of function
profoundly influences homomeric interaction behavior of PrP with
an expanded octarepeat domain. Amultimeric cluster of prion pro-
teins carrying expanded octarepeat domains may therefore capture
and incorporate spontaneously arising short-lived PrPSc-like con-
formers, thereby providing a matrix for their conversion.
Prion diseases are transmissible neurodegenerative diseases that,
uniquely, in humans can be of genetic, sporadic, or infectious origin.
Cases of the most prevalent human prion disease, Creutzfeldt Jakob
disease (CJD),2 are15% genetic, 85% sporadic, and only1% linked to
infection. In genetic or familial CJD (fCJD), germ line mutations in the
prion protein gene (PRNP) initiate a neurodegenerative disease that
subsequently becomes transmissible (1, 2). This phenomenon has not
been reported for other mammalian prion diseases that are more prev-
alent and seem to have mostly an infectious origin (1, 3). Major animal
prion diseases include scrapie of sheep and goats, bovine spongiform
encephalopathy of cattle, and chronicwasting disease ofAmericanmule
deer and elk. Transmissibility between species is limited and regulated
by a species barrier that is determined by genetic differences in the
PRNP gene and eventually by other genes (4, 5). In contrast to the seem-
ingly exclusive occurrence of genetic prion disease in humans, polymor-
phisms in PRNP are known to occur in many species and to influence
prion infection susceptibility (3).
The essential molecular component of prions is PrPSc, a pathological
conformer of the prion protein that replicates without the need for nucleic
acids (1). Once initiated, the prion replication mechanism is characterized
by the conformational conversion of the cellular (“normal”) isoform of the
prionprotein (PrPC) intoPrPSc,which in turn induces further conversionof
PrPC, thus propagating the PrPSc conformation (1). Currently, 55 patho-
genic mutations have been identified that cause inherited CJD in humans.
Of those, 24 are missense mutations and 27 are insertion mutations con-
sisting of up to 9 additional 24-bp repeats and corresponding to an increase
(“expansion”) in the number of octarepeats, of which there are normally
four consecutive copies (3). Interestingly, the clinical phenotype of fCJD
with insertional mutations can mimic that of Huntington disease in the
early phases of the disease (6).
Attempts at rebuilding genetic mutations that cause fCJD in cell or
animal models in order to reproduce de novo prion genesis have not
been successful so far (7), suggesting that either unknown factors in the
human genetic background or lifespan contribute to genetic prion for-
mation. Prion initiation, meaning de novo generation of infectivity by
spontaneous conversion of PrPC to PrPSc without template, and prion
propagation, i.e. conversion of PrPC to PrPSc in the presence of PrPSc
template, are likely to involve two different molecular mechanisms,
both remaining as yet unresolved. Although it has long been possible to
maintain prion propagation continuously in animals (8) and in cell cul-
ture (9, 10), only recently have there been significant advances in repro-
ducing both prion initiation and propagation in vitro (11, 12).
Elucidating the NMR structure of the recombinant prion protein
produced in Escherichia coli has been instrumental in determining the
structural effects of disease-linked amino acid changes (13, 14). The
mature prion protein (residues 23–231) can be divided into an N-ter-
minal (23–120) and a C-terminal domain (121–231) (13). Whereas the
C terminus adopts a mainly -helical globular conformation, the N
terminus is largely disordered (14), although itmay adopt a non-random
conformation at physiological pH (15). The most prevalent missense
mutations causing fCJD are localized in the C-terminal domain and
clustered at the edges of -helical structures. However, recombinant
PrP carrying disease-linked amino acid substitutions is not thermody-
namically destabilized (16), pointing to a diseasemechanismmore com-
plex than mere misfolding.
TheN-terminal domain contains four highly conserved copper bind-
ing octarepeats (ORs) of the sequence PHGGGWGQ (single letter
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amino acid code; residues 60–91). These are flanked by one nonarepeat
(residues 51–59; PQGGGTWGQ) and one partial repeat (residues
92–98; GGGTHNQ) that could bind copper as well (17). The OR
domain binds copper in a cooperative manner at physiological pH and
undergoes a distinct conformational change as a result, whereas copper
affinity is abolished below pH 6 (18, 19).
The N-terminal domain of PrP, including the OR domain, is of little
importance for prion propagation because removal of theN terminus from
PrPSc by partial protease digestion does not significantly alter infectivity
titers (20). Likewise, transgenic mice expressing PrP constructs with a
deleted OR domain on the PrP knock-out background can still produce
infectious prions, albeit with increased incubation times and reduced prion
titers when inoculated with full-length prions (21–24). The redundancy of
theOR domain for prion propagation stands in contrast to its genetic link-
age to fCJD when the OR domain is expanded (25–27), indicating that the
OR region does play a decisive role in prion initiation (28).
Our goal was to investigate the pathogenesis of fCJD by determining
how OR domain expansion, being the result of an insertional mutation,
starts the PrP misfolding pathway and ultimately leads to the formation
of infectious prions. In a series of biochemical and biophysical experi-
ments, we demonstrated how theORdomainmediates copper-depend-
ent and -independent homomeric interactions between PrP molecules.
OR domain expansion changes these properties in such away that bind-
ing between OR domains is no longer fully reversible and binding to
PrPSc instead of PrPC is favored. Thus, by preferentially interacting with
PrPSc, PrPC with an expanded OR domain may have a higher likelihood
of undergoing conversion, thereby facilitating development of fCJD.
EXPERIMENTAL PROCEDURES
Cloning
SyHaPrP-8OR, -10OR, and -16OR fragments were assembled from
the following oligonucleotides: 1) phos-5-GGCTGGGGGCAGCCCC-
ATGGTGGT-3, 2) phos-5-CTGCCCCCAGCCACCACCATGGG-
G-3, 3) phos-5-GGATCCGCGCGCGCGC-3, 4) phos-5-GGCTG-
GGGGCAGTGATAAGAATTCGAGAGAGAGA-3, 5) 5-GCGCG-
CGCGCGGATCCCCCCATGGTGGT-3, and 6) TCTCTCTCTCG-
AATTCTTATCA. First, we ligated oligonucleotides 2, 3, and 5 (10 M
each in 10 l) using Taq ligase (New England Biolabs; 45 min, 45 °C).
This ligation mix was then diluted 1/50 (mol/mol) in a mix of primers 1
and 2 (20M each, in 10l), followed by further ligation withTaq ligase
(1 h, 40 °C).We then added primers 4 and 6 (250 nmol each) and ligated
withT4 ligase (16 h, 16 °C). The resultingmixturewas separated on 1.5%
Tris borate-EDTA-agarose, and all fragments 200 bp were collected.
The wild-type SyHaPrP-(23–98) and SyHaPrP-(52–98) fragments were
amplified from pET-11a(SyHaPrP-(23–231)). Finally, all OR fragments
were cloned into the pGEX-4T-3 expression vector (Amersham Bio-
sciences) at BamHI/EcoRI. All cloned constructs were verified by
sequencing on an ABI Prism (PerkinElmer).
Recombinant Protein Expression and Purification
Free GST (vector only), GSTHD20, GSTHD51, and GSTOR fusion
proteinswere expressed in BL21(DE3) according to standardmethods.
Following lysozyme lysis, the suspensionwas brought to 50mMTris, pH
8, 150 mMNaCl, 20 mM EDTA, 1% Triton X-100, 0.2% sarkosyl, cleared
(20 min, 20.000  g), and affinity purified on glutathione-Sepharose
(Amersham Biosciences). After elution, all proteins were directly
treated with iodoacetamide (50 mM, 30 min, room temperature) to
block free Cys residues on the GST moiety. The GSTOR fusions were
further purified on Zn2-nitrilotriacetic acid (NTA)-agarose (Nova-
gen). All proteins were then extensively dialyzed against 10 mM KPO4,
pH 7.5, 0.1mMEDTA. SDS-PAGE analysis confirmed that batches of all
GSTOR fusion proteins were consistently purified to homogeneity and
migrated at their expected molecular masses (Table 1).
Covalent Coupling of GSTOR Fusions to Sepharose andOR Peptides
to BSA
Coupling to Sepharose—GST, GSTHD20, GSTHD51, and GSTOR
proteins were covalently coupled to N-hydroxysulfosuccinimide-acti-
vated Sepharose (Amersham Biosciences) in 50 mMKPO4, pH 7.5, 0.3%
sarkosyl, 50 M EDTA (2 h, room temperature) at a protein concentra-
tion of 0.5 mg/ml and a coupling density of 5 mg/ml.
Peptide Synthesis—Peptides corresponding to SyHaPrP-(55–67)
(1OR) and SyHaPrP-(55–98) (4OR) were synthesized by the Biomediz-
inisches Forschungszentrum at the University of Du¨sseldorf.
Coupling to Bovine Serum Albumin—1OR and 4OR peptides were
linked to succinimidyl-acetylthioacetate (Sigma) and then combined
with BSA (Bio-Rad) derivatized with succinimidyl-4-(N-maleimidom-
ethyl)-cyclohexane-1-carboxylate (Molecular Probes) at a 1/10 (mol/
mol) ratio in 50 mMNaPO4, pH 8, 50 mM hydrazine (2 h, room temper-
ature). SDS-PAGE analysis showed that BSA-1OR/4OR conjugates
carried several OR peptides each (data not shown).
Pulldown of PrPC and PrPSc from Brain Extracts with Immobilized
GSTOR Fusions
Capture of PrPC and PrPSc—Normal hamster (NHa) or scrapie-in-
fected hamster (ScHa; 263 K strain) brain homogenates (20% w/v stock
in 50 mM HEPES, pH 7.5, 100 KAc, 250 mM sucrose, 5 mM MgCl2, 5
protease inhibitors (Roche Applied Science), 1 mM phenylmethylsulfo-
nyl fluoride) were diluted to 0.5% (NHa) or 1% (ScHa) in binding buffer,
pH 7.5 (50mMHEPES, 10mMTris, pH 7.5, 300mMNaCl, 0.6%Nonidet
P-40, 0.3% sarkosyl) or binding buffer, pH 5.5 (100 mM NaAc, pH 5.5,
300 mM NaCl, 0.6% Nonidet P-40, 0.3% sarkosyl), both containing 1
protease inhibitors and either 50–200 M CuSO4/ZnSO4 or 5 mM
EDTA, and then cleared (5 min, 10,000  g). Sepharose beads coated
with GST, GSTHD20, GSTHD51, or GSTOR (20 l) were combined
with 0.5 ml of NHa or 1 ml of ScHa extract and incubated overnight at
4 °C. Beads incubated with NHa extract were washed and then boiled in
2 SDS-PAGE sample buffer. Beads incubated with ScHa extract were
first split, i.e. half was boiled directly, while the other half was digested
with 20g/ml PK (Merck) for 1 h at 37 °C in binding buffer, pH 7.5, plus
5 mM EDTA (stopped with 5 mM phenylmethylsulfonyl fluoride) prior
to boiling. Sampleswere run on 12.5% SDS-PAGE, and blots were devel-
oped with a PrP monoclonal antibody 3F4 (29).
Removal of PrPC from PrPSc—Sepharose beads coated with
GST16OR (20 l) were incubated with ScHa extract (buffer, pH 7.5,
plus 5mMEDTA) obtained from infected hamsters in the terminal stage
(low PrPC/PrPSc ratio) or 42 days after infection (high PrPC/PrPSc ratio).
Beads werewashed and then elutedwith 50ml of 20mMHEPES, pH 7.5,
1 mM EDTA, 0.25–1.5% SDS (10 min, room temperature). After collec-
tion of the eluate, beads were washed with a further 1 ml of SDS buffer
and then boiled.
HaPrP Enzyme-linked Immunosorbent Assay—For calibration, a
stock solution of 0.5 mg/ml recHaPrP-(23–231) (30) was freshly diluted
to 50–0.5 ng/ml in 100 mM NaHCO3, pH 8.3, 7 M guanidinium HCl
(GuHCl buffer) and coated onto Maxisorp plates (Nunc) overnight at
room temperature. After blocking, wells were probed with monoclonal
antibody 3F4 in 50 mM Tris, pH 8, 150 mMNaCl, 1 mM EDTA, 1% BSA,
0.1% Tween 20, 0.1% Nonidet P-40 (2 h, room temperature) and then
with peroxidase-labeled anti-mouse IgG (Pierce) in the same buffer (1 h,
room temperature). Plates were developed with TMB substrate
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(Pharmingen; 15min, room temperature) according to themanufactur-
er’s protocol.
Quantification of GST16OR-bound PrPSc by Sequential Pulldown—1
ml of 1% ScHa extract was sequentially incubated with two batches of
150 g of Sepharose-linked GST16OR (overnight, 4 °C). In parallel, we
incubated ScHa homogenate (diluted), the pellet thereof (resuspended
in 1 ml of binding buffer, pH 7.5), and extract without Sepharose beads.
These samples, in parallel with the extract after GST16OR pulldown,
were digested with PK (20 g/ml, 1 h at 37 °C), after which PrPSc was
pelleted (1 h, 120,000  g) and washed once with 1 ml of 100 mM
NaHCO3, pH 8.3. Pellets were then taken up in 200 l of GuHCl buffer.
Following pulldown, beads were washed with binding buffer, pH 7.5,
and 100 mM NaHCO3, pH 8.3, and then PK digested and subsequently
extracted with 200 ml of GuHCl buffer. The PrP content of all GuHCl
samples was determined by enzyme-linked immunosorbent assay as
described above.
Size Exclusion Chromatography
Purified GST4OR, GST10OR, and GST16OR (3 mg/ml) were frac-
tionated on a HiPrep 16/60 Sephacryl S-200 HR column (Amersham
Biosciences) at 0.5ml/min in binding buffer, pH7.5, plus 5mMEDTAor
in 20 mM NaAc, pH 5.5, 2 mM EDTA, 0.3% sarkosyl using a Biologic LP
system (Bio-Rad). Calibration was done using size exclusion chroma-
tography (SEC) standards (Bio-Rad). Fractionswere analyzed on 4–20%
SDS-PAGE gels (Bio-Rad), stained overnight with SYPRO Ruby
(Bio-Rad).
Dynamic Light Scattering
Dynamic light scattering (DLS) measurements were performed on a
DynaPro-MS/Xmachine (Protein Solutions). BSA, BSA-1OR, andBSA-
4OR were diluted to 30–250 g/ml in 50 mM HEPES, pH 7.5, 150 mM
NaCl, supplemented with either 200 M CuSO4 or 2 mM EDTA. GST
and GSTOR fusions were measured at dilutions of 100–1000 g/ml in
50 mM HEPES, 5 mM EDTA, or in 100 mM NaAc, pH 5.5.
Scanning ForceMicroscopy
GSTOR fusions were deposited on a freshly cleavedmica surface in 5
mM HEPES/MES, pH 7.9/5.5, 3 mM KCl, 5.5 mM MgCl2, air-dried, and
analyzed as described (31).
Animal Inoculations
Syrian Gold hamsters (6–8 weeks old) were inoculated intracere-
brally using a 24-gauge needle (four or five hamsters each group) with
the following material. (A), starting material: 1 ml of 1% ScHa brain
extract (263 K) in binding buffer, from which PrPSc was collected by
ultracentrifugation (45 min, 100,000  g in an Optima table ultracen-
trifuge (BeckmanCoulter)) and subsequently washed twice with 70%
ethanol and twice with sterile PBS. (B), beads coated with GST16OR
(see above) that had been incubated overnight in ScHa extract produced
as in (A) and then washed three times in binding buffer, twice with 70%
ethanol, and twice with sterile PBS. (C), 1 ml 1% ScHa brain extract in
binding buffer after pull downwith GST16OR prepared as described in
(A). (D), as a negative control, GST4OR beads were prepared as in (B).
(E)As another negative control, GSTbeadswere prepared as for (B). For
(B), (D), and (E), we choose to inoculate thewhole bead fraction in order
to investigate all infectivity captured and to avoid manipulating infec-
tivity by elution procedures. Animals were examined daily for standard
neurological symptoms and were sacrificed because of animal protec-
tion aspects when severe clinical symptoms were observed. The animal
experimentation protocol had been approved to Lothar Stitz.
RESULTS
The Wild-type Prion Protein OR Domain Is a Reversible, Copper-de-
pendent Self-association Domain—First, we established the copper-de-
pendent mode of the homomeric interactions between OR domains.
Glutathione S-transferase (GST) fusion proteins, in which GST was
linked N-terminal to SyHaPrP N-terminal fragments with different OR
lengths (Table 1) were used to circumvent poor solubility of both wild-
type and expanded OR domains when present as free polypeptides or
within full-length PrP (data not shown). Because the octarepeat
sequences of human and hamster PrP are identical, we considered these
constructs to be valid models for investigating biochemical characteris-
tics of theOR domain in human PrP.We covalently coupledGST alone,
GST with four ORs (GST4OR), and GSTwith sixteen consecutive ORs
(GST16OR) to Sepharose via amine linkage, thus ensuring that only the
GST moiety was bound to the solid support. GST16OR was used as a
model protein for expanded OR domains as occurring in fCJD, where
the maximum number of ORs reported so far is 14. When incubated
with brain extract from normal, non-infected hamsters (NHa) in sarko-
syl-containing buffer (0.3%), both the GST4OR and GST16OR cap-
tured PrPC in the presence of copper ions at pH 7.5 with a half-maximal
effect between 75 and 125 M (Fig. 1A). However, unlike GST4OR,
GST16OR still retained PrPC even in the absence of copper ions (Fig.
1B), suggesting partial loss of copper-dependent reversibility for PrP
binding. Under the conditions used here, the full N-terminal fragment
PrP-(23–98) expressed as a fusion protein to GST (GSTSyHaPrP-(23–
98)) showed essentially the same effect as GST4OR (data not shown),
demonstrating that the OR domain alone is sufficient for PrPC binding.
Experiments performed with zinc yielded the same results as copper
over the same concentration range.
To establish whether OR domains could interact directly in solution
and to analyze the critical OR length needed for such an interaction, we
covalently linked synthetic 1OR (residues 55–67) and 4OR (residues
55–98) peptides via amine linkage to BSA and analyzed copper-depend-
entOR-OR interactions in vitro byDLS. In the absence of copper ions (2
mMEDTA), the hydrodynamic diameters (DH) of BSA alone, BSA-1OR,
TABLE 1
Description andmeasured particle sizes of GSTOR fusion proteins
The synthetic 8OR, 10OR, and 16OR inserts contain multiples of the PHGGGWGQ repeat. Properties shown are calculated molecular mass and hydrodynamic diameter
(DH S.D., in nm) and corresponding molecular mass as measured by dynamic light scattering at pH 7.5 and 5.5.
Construct Calculated molecular mass Measured DH andmolecular mass at pH 7.5
Measured DH and
molecular mass at pH 5.5
kDa nm/kDa nm/kDa
GST 26.2 5.4 0.2/34 4
GSTSyHaPrP-(23–98) (4OR) 33.7 6.8 0.2/59 4
GSTSyHaPrP-(52–98) (4OR) 30.7 6.0 0.2/44 4
GST8OR 32.5 10.6 0.6/170 25
GST10OR 34.1 15.8 0.4/420 30 7.8 0.3/79 8
GST16OR 38.7 21.2 0.6/840 60 10.6 0.6/170 25
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and BSA-4ORwere 7.5 0.4 nm (70 10 kDa), indicating that all three
conjugates were essentially monomeric. Adding copper ions (200 M
CuSO4) caused BSA-4OR, but not BSA or BSA-1OR, to associate into
large, heterogeneous particles (DH 85 nm), indicating binding
between BSA-4OR conjugates, each carrying several peptides. These
results demonstrated that 4OR, but not 1OR, peptides directly self asso-
ciate in the presence of copper ions, presumably because of the confor-
mation-inducing effect of copper binding on the OR domain (19). We
were unable to determine the effect of copper on the size distribution of
GSTOR proteins by DLS as GST itself was no longer monodisperse in
the presence of copper, thus prohibiting reliable data collection.
The Expanded OR Domain as in fCJD Leads to the Formation of
Distinct Multimeric Complexes—When we examined GST16OR by
DLS in the absence of copper ions, we found that it was present as a
monodisperse multimeric complex with a DH of 21.2 0.6 nm, corre-
sponding to 850  50 kDa at pH 7.5 (Table 1). Under the same condi-
tions, GST alone and GST4OR were measured to be essentially mono-
meric (Table 1). These findings demonstrate thatORdomain expansion
brings about new homomeric interactions that are copper independent
and ordered in nature. Interestingly, GSTOR proteins with intermedi-
ate OR lengths also formed particles of intermediate size: GST8OR and
GST10OR had diameters of 10.6 0.6 nm (160 30 kDa) and 15.8
0.4 nm (420  30 kDa), respectively, demonstrating a gradual effect of
OR length on multimerization. Upon lowering the pH to 5.5, multim-
eric GST16OR readily dissolved into lower molecular mass complexes
with a DH of 10.7 0.6 nm (170 30 kDa). Likewise, GST10OR mul-
timers converted to monomer- or dimer-like particles (Table 1), con-
firming that higher order multimerization by the expanded OR domain
is a phenomenon that only occurs at physiological pH.
Our DLS findings onmultimerization of expandedOR domains were
confirmed by scanning force microscopy and SEC (Fig. 2, A and B,
respectively). Scanning force microscopy analysis demonstrated that,
compared with GST4OR, all (detergent-free) GST10OR and
GST16OR multimers appeared as essentially homogenous, spherical
particles and not as, for instance, fibrillar species (Fig. 2A). Indeed, puri-
fied GST16OR did not bind thioflavin T, indicating that these multim-
ers were not amyloid like (data not shown). Quantitative analysis of
scanning force microscopy images showed that GST16OR multimers
had a diameter of 46.3  9.8 nm (Fig. 2A); this apparent discrepancy
with the multimer size determined by DLS (21 nm) was most likely
because of tip convolution effects. Furthermore, SEC analysis demon-
strated that GST16OR multimers, but not those of GST10OR, were
stable in 0.3% sarkosyl and that GST16OR multimers converted to
oligomers at pH 5.5 (Fig. 2B) in a manner that was consistent with our
DLS measurements. Taken together, our results demonstrate that OR
domains containing at least 8 repeats can formhomogenousmultimeric
complexes of distinct size under physiologically relevant conditions,
indicating that increasing the number of ORs favors the formation of
stable homomeric complexes of PrP.
TheMutant Expanded, but NotWild-type, ORDomain Binds PrPSc—
Wewent on to investigate whether, in parallel tomultimerization, wild-
type and expanded OR domains differed in their interaction with PrPSc,
FIGURE 1. The OR domain is a copper-dependent self-association domain. A, West-
ern blot of pulldown experiments with Sepharose-bound GST, GST4OR, and GST16OR
from normal hamster extracts in the presence of copper. Per lane, pulldown from 0.5 ml
of 0.5% NHa extract in binding buffer, pH 7.5, plus 5 mM EDTA (ED) or 50–200 M CuSO4
as indicated. GST4ORandGST16ORbothpull downPrPC in thepresenceof copper ions.
B, longer exposureof film reveals that onlyGST16ORalsopulls downPrPC in the absence
of copper ions. None, no additives; ED, plus 5 mM EDTA.
FIGURE 2. GST expanded OR fusion proteins
form distinct multimeric complexes. A, scan-
ning force microscopy analysis of GST4OR,
GST10OR, and GST16OR at pH 7.9 or 5.5 (as indi-
cated). A gradual, pH-dependent multimerization
from GST4OR to GST16OR is observed. B, protein
stain (SYPRO Ruby; Bio-Rad; negative image) of
fractions from SEC analysis of GST4OR, GST10OR,
and GST16OR (as indicated on left side, lane L
shows starting material) on a HiPrep 16/60
Sephacryl S-200 HR column. Calibrated molecular
mass standards are indicated in the top row.
Whereas GST4OR and GST10OR are essentially
monomeric, GST16OR has a size of 250 kDa at
pH 7.5 and between 170 and 200 kDa at pH 5.5.
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which could indicate that the expandedOR domain stabilizes this path-
ological conformation. When we incubated Sepharose-immobilized
GSTOR fusion proteinswith brain extract fromScHa in the presence of
sarkosyl-containing buffer, we observed that only GST16OR captured
PrPSc at pH 7.5 in the absence of copper ions (Fig. 3, A and B), demon-
strating selective interaction of the expanded OR domain with PrPSc.
Adding copper or zinc (200 M CuSO4/ZnSO4) or lowering the pH to
5.5 during incubation essentially abolished PrPSc binding. As controls,
we verified that both GSTHD20 and GSTHD51, GST fusion proteins
with the huntingtin exon-1 polypeptide containing a sequence of 20 or
51 glutamine residues, respectively (32), did not bind PrPSc (Fig. 3A for
GSTHD51, GSTHD20 data not shown), thereby ruling out nonspecific
interactions with PrPSc. At pH 5.5, GST16OR did not bind protease-
resistant PrPSc (Fig. 3B), but both the GST4OR and, especially,
GST16OR did bind PK-sensitive PrP, possibly PrPC.
AThreshold of 10OR in the ExpandedORDomain Establishes a PrPSc
Binding Site—To determine how many consecutive ORs were needed
for the emergence of the PrPSc binding site in the expandedOR domain,
we performed pulldown experiments from ScHa brain extracts with
GSTOR proteins of different OR lengths. We observed a clear thresh-
old effect, namely a complete switch from no to full PrPSc binding
between eight and ten ORs (Fig. 3C). Remarkably, ten ORs has previ-
ously been reported to be the minimum number of OR to be required
for transmissibility in fCJDwith expandedOR (28). As with GST16OR,
the presence of copper ions inhibited binding of PrPSc to GST10OR.
Having shown by SEC analysis that GST10OR was not multimeric
under binding conditions used here, we conclude that it is an intrinsic
conformational change of the expandedOR domain that creates a PrPSc
binding site rather than its multimerization.
Resistance to Denaturing Buffer Conditions Demonstrates Tight Bind-
ing between PrPSc and the Mutant, Expanded OR Domain—Because
GST16OR bound both PrPC and PrPSc at physiological pH and in the
absence of copper ions, both forms were invariably retained during a
pulldown experiment from ScHa extract (Fig. 3A). To investigate differ-
ences between PrPC and PrPSc binding to GST16OR and to define con-
ditionswhereGST16OR could select between the two PrP isoforms, we
tested a range of washing buffers for their ability to remove PrPC while
FIGURE 3.AnexpandedORdomainof at least 10 consecutive repeats binds PrPSc.A,
Western blot of pulldown experimentswith Sepharose-boundGST, GSTHD51, GST4OR,
and GST16OR (as indicated) from ScHa extracts in the presence of 200M CuSO4 (Cu) or
5mM EDTA (ED) at pH 7.5. GST16ORbinds PK-resistant PrPSc in the presence of EDTA. No
binding was observed by either construct at pH 5.5 (B). C, pulldown experiments using
GSTOR proteins with 4, 8, 10, and 16 repeats (as indicated in top row) show that only
GST10OR or GST16OR bind PrPSc. A–C, PK-digested samples (upper panel) and undi-
gested samples (lower panel).
FIGURE 4. The GST16OR-PrPSc complex is SDS-resistant, whereas the GST16OR-
PrPC complex is not.Western blot of eluted (E) and bound PrP (B) after washing beads
from pulldown experiments with Sepharose-bound GST16OR from normal hamster
(NHa) extract (upper panel) or scrapie-infected hamster (ScHa) extract (lower panel) with
0.25–1.5% SDS (as indicated on top). ScHa brains were from terminally ill hamsters (A) or
asymptomatic hamsters at day 42 after inoculation (B). Whereas PrPC is removed with
0.5% SDS (upper panels), only PrP from scrapie-infected hamsters (presumably PrPSc)
remainsbound tobeads (lowerpanelA). SDS-resistantbindingofPrPScwasalsoobserved
when only small amounts of PrPSc were present in the brains of asymptomatic inocu-
lated hamsters (lower panel B).
FIGURE 5. GST16OR binds a small fraction of total PrPSc. Western blot of pulldown
with Sepharose-boundGST16OR fromScHa extracts in binding buffer, pH 7.5, plus 5mM
EDTA. Each lane corresponds to 0.5ml of 1% ScHa extract. The startingmaterial (w/o PD)
and extract after pull down (after PD) were PKdigested andultracentrifuged to collect all
PK-resistant PrPSc. Two sequential pulldowns with GST16OR (1st PD and 2nd PD) from
the starting material were performed. Of each pulldown, half of the beads were PK
digested (PK) and the other half eluted directly by boiling in 2 SDS-PAGE sample
buffer (PK). The blot shows that only a fraction of PK-resistant PrP present in starting
material was captured (compare w/o PD to 1stPK) and that the second pulldown did
not yield additional PK-resistant PrP (compare 1st to 2ndPK).
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retaining PrPSc. We found that PrPC could be removed by washing with
at least 0.5% SDS, while leaving PrPSc bound to GST16OR (Fig. 4A).
Attempts at achieving the same kind of separation using sarkosyl (5%),
urea (10 M), high ionic strength (1 MNaCl), low pH (10% acetic acid), or
copper ions (up to 200 M) were unsuccessful (data not shown). By
means of the SDS washing technique, we were able to detect a small
amount of PrPSc in ScHa extract even at a high PrPC/PrPSc ratio, namely
in brain homogenates from asymptomatic scrapie-infected Syrian ham-
sters (culled at day 42 after inoculation of a 60-day incubation period;
Fig. 4B). These results clearly show how effectively PrPSc is captured by
the expanded OR domain even when relatively low levels of PrPSc are
present in early stages of disease.
The Expanded OR Domain Recognizes a Distinct Subpopulation of
PrPSc Molecules—To investigate how efficient recruitment of PrPSc by
expanded octarepeats was, we quantified the amount of PrPSc that we
could pull down from ScHa brain extracts. Surprisingly, only a small
fraction of the total amount of available PK-resistant PrPSc was pulled
down (Fig. 5). When the supernatant of the first pulldown was again
probed with GST16OR, no additional PK-resistant PrPSc was bound,
indicating that the first round had depleted the brain homogenate of a
particular PrPSc species present in the “total” PrPSc population under the
experimental conditions used here (Fig. 5). Quantification of the pulled
down fraction by enzyme-linked immunosorbent assay demonstrated
that this GST16OR-specific PrPSc species made up 4% of the total
amount of PK-resistant PrPSc present in the extract that itself contained
70% of total PK-resistant PrPSc in ScHa brain. The PrPSc species pulled
down consisted of full-length PrPSc that was primarily double glycosy-
lated, although other PrP glycoforms were also pulled down (see Figs. 3,
4, and 5). On undigested pulled down samples, no PrP fragments could
be detected, indicating that the subpopulation of PrPSc pulled down
consisted mostly of full-length PrP. When that material was protease
digested, a shift in PrP immunoreactivity with an electrophoreticmobil-
ity similar to that of the starting material was observed (see Fig. 5) and
there was no decrease in signal intensity, demonstrating that all pulled
down material consisted of protease-resistant full-length PrPSc. Thus,
the pulled down PrPSc fraction probably corresponded to a particular
conformation within a seemingly heterogenous population of PrPSc.
These data parallel those under “Results” (Figs. 2 and 3) where we found
that an OR length-dependent conformational change in the expanded
OR domain rather than multimerization of GSTORmolecules created
the novel PrPSc binding site (Figs. 2 and 3).
GST16OR pulled down material inoculated into Syrian Gold ham-
sters demonstrated infectivity with an average time to death of 89  7
days (4 of 4 hamsters dead, compared with 77  5 days for starting
material or material after GST16OR extraction). Because incubation
time of the GST16OR-captured infectivity was significantly shorter
than that of negative controls (GST4OR, 98  12 days to death (Stu-
dent’s t-test p 0.001); GST alone, 107  19 days to death (Student’s
t-test p 0.001)), these experiments indicate that the PrPSc species
pulled down was associated with infectivity. The presence of infectivity
in negative controls was unavoidable because the beads could not be
washed harshly enough without interfering with prion infectivity itself.
Our results thus provide evidence for the heterogeneity of the PrPSc
population. To our knowledge, GST16OR is the first ligand described
that specifically targets an infectious subpopulation of PrPSc.
DISCUSSION
Expansion of the OR domain profoundly changes the reversible,
homomeric, and copper-dependent interactions that are mediated by
the N-terminal OR-containing domain of PrP. Our studies identified
three new features that arise fromORdomain expansion, namely partial
loss of reversibility of copper-dependent interaction, gain of a PrPSc
binding site, and gradual multimerization ability. Although our data do
not reveal how the expanded OR directs protein misfolding of PrPC to
PrPSc, our results permit us to propose amodel for the events preceding
prion conversion in fCJD with insertional mutations (see Fig. 6). Our
model addresses interactions between mutant PrP molecules and how
these could favor prion conversion but does not relate to any intrinsic
conformational shift toward PrPSc that might be brought about by OR
domain expansion. In the presence of copper and at physiological pH,
the OR domain with wild-type 4 ORs undergoes transient, reversible
homomeric interactions with PrPC but not with PrPSc (see also Fig. 3).
FIGURE 6. Schematic drawing of how expanded OR domains change homomeric interactions of the N-terminal domain of PrP to favor conversion to PrPSc in fCJD. PrPC
conformation in circles, PrPSc conformation in squares. N-terminal domain depicted as non-coordinated (loose tails) or copper coordinated (round tails). Amultimeric cluster of prion
proteins carrying expanded octarepeat domains may therefore capture and irreversibly incorporate spontaneously arising short-lived PrPSc-like conformers and thereby provide a
matrix for their conversion.
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This interaction mode is based on a conformational change in the OR
domain that is induced by copper binding (19). The expanded OR
domain behaves in the same way, with the exception that it does not
fully release PrPC upon copper depletion. In the absence of copper, the
wild-type OR domain loses all affinity for PrPC, whereas the expanded
domain now tightly binds PrPSc and forms distinct multimers. When
these two properties act either simultaneously or consecutively, it is
likely that incorporating PrPSc or transient PrPSc-like conformers into a
multimeric complex forms a nucleus for further PrPSc formation by
favoring conversion.Our findings are paralleled in the prion-like (PSI)
determinant of yeast where a similar oligopeptide repeat PQG-
GYQQYN in Sup35 stabilizes intermolecular prion interactions and can
be functionally replaced by themammalian octarepeat peptides (33, 34).
The reversible, copper-dependent interactions of the wild-type
four-OR repeat domain makes us think of a “copper switch.” Only four
Ors, but not one single OR peptide, constitute a copper switch, suggest-
ing that the copper-induced conformational change of the OR domain
as a whole rather than copper coordination alone is responsible for self
association, in amanner similar to what has been reported by Viles et al.
(19). Of note, it was found that PrP with nine extra ORs recombinantly
expressed in cells did not undergo copper-induced endocytosis,
whereas wild-type PrP did (35). This observation is consistent with a
loss-of-function phenotype and with our finding that OR domain
expansion interferes with the reversibility of the wild-type copper
switch that might be crucial for this type of endocytosis. The ultimate
purpose of reversible interactions of PrPwith itself or othermolecules is
unknown, but from our results it is clear that these interactions are
imbalanced when the OR domain is expanded by insertional mutations
(see Fig. 6). Physiologically relevant reversible interactions of the OR
domain would explain why the OR domain has been highly conserved
during evolution by selecting against dysfunctional OR domains that
contain more (or less) than the optimal four consecutive repeats.
Our findings can directly be related to clinical and neuropathological
data from patients with fCJD with insertional mutations, thus offering a
novel and intriguing mechanistic explanation for these phenotypes. An
increased number of OR in fCJD cases decreases the age of onset of
disease and duration of disease (3, 36). Moreover, it has been reported
that brain tissue from fCJD patients carrying OR insertional mutations
varies in infectivity, with the more expanded OR domains transmitting
disease more efficiently (28, 37). These clinical phenotypes are paral-
leled by our results that show how multimerization progresses with
increasing OR length and how PrPSc recruitment only occurs effectively
with an OR length 10. Consequently, the combination of PrP mole-
cules carrying an expanded OR domain together with PrPSc or PrPSc-
like conformers in one stable multimeric complex might facilitate fur-
ther conversion to such an extent that the disease process is set in
motion spontaneously. Our in vitro data are consistent with earlier
experiments in which SyHaPrP with different OR lengths was tran-
siently expressed recombinantly in cells. There, with insertional muta-
tions at a threshold of at least sevenOR, PrP became increasingly aggre-
gated and developed a weak protease resistance (38).
Recapitulating our observations on the multimerization and PrPSc
binding behavior of expandedOR domains, we would like to stress their
specific nature and thereby their relevance to disease. First of all, the
homogenous nature and strict pH dependence of GST16ORmultimers
point to a degree of internal order and regular subunit structure that sets
them apart from “random” or nonspecific aggregates. Taking this into
account, our next three observations argue for a specific interaction
between the expanded OR domain and PrPSc. First, there is a complete
switch from no to full PrPSc binding upon going from eight to ten ORs.
Such an effect is unlikely to reflect nonspecific binding, as that is
expected to show a more gradual increase. Second, GST16OR exclu-
sively binds a small and depletable subfraction of the overall amount of
PK-resistant PrPSc. Such binding behavior is equally unlikely to stem
from a nonspecific interaction between multimeric GST16OR and a
“sticky” target. In fact, such selectivity has not been reported for any
other PrPSc-specific ligand (39, 40). Third, both GSTHD20 and
GSTHD51, GST fused to mammalian polyglutamine-containing pro-
tein fragments with low and high aggregate/amyloid-forming propen-
sity (32), respectively, lack all PrPSc binding ability. The PrPSc fraction
purified with GST16OR retained infectivity, thus excluding the possi-
bility that a biologically irrelevant fraction of protease-resistantmaterial
had been isolated. The fact that the complex between GST16OR and
PrPSc is resistant to harsh or denaturing conditions may be because the
GST16OR multimer offers a very large and multifaceted binding sur-
face formultimeric PrPSc, causing it to become kinetically trapped, espe-
cially when several GST16OR multimers participate in binding.
Whether missense mutations causing other forms of fCJD could also
act by recruitment of PrPSc and subsequent conversion enhancement is
unclear. Nevertheless, the report that PrP with expanded OR domains,
but not othermissensemutations, converts PrPC fromnon-mutant alle-
les (41) suggests that such a mechanism may be unique to fCJD with
insertional mutations. Until now, animal models have failed to accu-
rately mimic genetic prion disease. For example, a transgenic mouse
strain (Tg(PG14)) expressing a nine-OR insertion homologue within
epitope-tagged MoPrP failed to generate spontaneous infectivity even
though these mice developed spontaneous neurodegenerative disease
and were susceptible to mouse-adapted prions (7). The inability to
mimic fCJD in a transgenic mouse model may be because of molecular
differences in host factors essential for prion propagation and/or
require mutated PrP to be expressed within the human amino acid
sequence and eventually within the human genetic background.
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